Payor Coverage: Page 2

Cleveland Diagnostics nabs Medicare coverage for test that interrogates PSA structural variants
By LabPulse.com staff writers
In large, prospective multicenter studies of men scheduled for biopsy, IsoPSA demonstrated greater diagnostic accuracy than PSA alone in identifying patients with high-grade cancer
October 13, 2022
Cancer Cells Prostate Social
Immunovia nabs CMS preliminary payment determination
By LabPulse.com staff writers
The CMS preliminary payment determination implied a test price of $897.
September 26, 2022
2022 07 08 16 10 0843 Research Money 400
ACLA campaign, letter seek to stop cuts in lab testing payments
By Leo O'Connor
ACLA said it is launching a series of digital advertisements as part of its Stop Lab Cuts campaign to urge Congress to pass the Saving Access to Laboratory Services Act.
September 12, 2022
2022 09 13 16 54 6353 Lab Vacutainer Test Tube 400
OncoCyte announces evaluation of gene expression test
By LabPulse.com staff writers
In a clinical trial, 429 patients diagnosed with metastatic urothelial cancer were treated with atezolizumab (Tecentriq, Genentech), an immune checkpoint inhibitor.
August 24, 2022
2022 04 18 13 42 3384 Dna Genome Gene Targeted 400
Labcorp acquires RWJBarnabas Health outreach services
By LabPulse.com staff writers
With the acquisition, physicians and patients will have access to an expanded test menu, Labcorp's network of patient service centers, expanded health plan coverage, and reduced out-of-pocket lab costs, the organizations said, adding that greater support, service, and same day and STAT testing will be available in rural and local communities.
August 23, 2022
2022 08 24 19 55 2385 Lab Scientist Biosafety 400
Caris Life Sciences to pay almost $2.9M in false claims lawsuit
By LabPulse.com staff writers
The Irving, Texas-based company delayed its submission of claims to the Centers for Medicare & Medicaid Services for its predictive biomarker tests, known as Caris Molecular Intelligence and the Adapt Biotargeting System, leading to additional expenses, the DOJ said.
June 1, 2022
2022 04 01 20 32 7374 Gavel Money 400
AACC lobbies against greater regulation of lab-developed tests
By Erik L. Ridley
The Verifying Accurate Leading-edge IVCT Development (VALID) Act would limit the availability of laboratory-developed tests, decreasing patient access to these diagnostic tools, the AACC said. Often created when there is no FDA-approved commercial test available, these tests are frequently used to diagnose rare conditions -- such as genetic abnormalities in children -- or to respond to emerging health threats such as COVID-19, according to the association.
May 24, 2022
2020 07 01 22 14 2802 Washington Dc Capitol 400
Lucid promotes new guideline from ACG on esophageal cancer
By LabPulse.com staff writers
The new guidelines include a reference to screening for esophageal cancer using Lucid's EsoGuard DNA test on samples collected with its EsoCheck Cell Collection device, it said.
April 3, 2022
2019 04 05 16 58 5171 Cancer Cell 400
PGDx receives updated Medicare rate for Elio test
By LabPulse.com staff writers
The Centers for Medicare & Medicaid Services finalized a national reimbursement rate of $2,919.60 for the proprietary laboratory analyses code (0250U) that PGDx obtained for the test, the company reported in a release.
January 27, 2022
2022 01 10 23 10 0651 Lab Test Tube Dna Blood 400
COVID-19 tests drove increase in Medicare spending in 2020
By Leah Sherwood
The HHS Office of Inspector General (OIG) found that total Medicare Part B spending has increased each year for the past five years. COVID-19 tests accounted for approximately 19% of total Medicare Part B spending on lab tests, while utilization of non-COVID-19 tests as a group decreased 15.9% from 2019. Spending on lab tests other than for COVID-19 in 2020 was the lowest it had been in the past five years (no other year prior to the pandemic had a decrease).
January 3, 2022
2021 02 25 23 48 3444 Covid Virus Dna Molecule 400
LabPulse.com Microbiology Insider
By Brian Casey
Diagnostic testing is key to controlling the COVID-19 pandemic, and the earlier that SARS-CoV-2 infection can be detected, the better. Researchers from Hong Kong believe they may have found an assay that detects SARS-CoV-2 at a much earlier stage of infection.
October 25, 2020
Report: LDT market to exceed $17B
By Bruce Carlson
The findings come from LabPulse.com sister company and IVD research firm Kalorama Information in a new report, "The Market for Clinical LDT Services and LDT Supplies." Kalorama noted that the LDT market is driven by relaxed regulatory activity and the need for improved cancer tests.
October 19, 2020
2019 07 26 20 46 7792 Lab Blood Woman 400
Previous Page
Page 2 of 5
Next Page